Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. - Wikidata - wikimedia - TriplyDB

Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics.

Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics.

http://www.wikidata.org/entity/Q31047131

about

Cerebrospinal fluid biomarkers of Alzheimer’s disease Stabilization of neurotoxic soluble beta-sheet-rich conformations of the Alzheimer's disease amyloid-beta peptide Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT Current neuroimaging techniques in Alzheimer's disease and applications in animal models Early life nutrient restriction impairs blood-brain metabolic profile and neurobehavior predisposing to Alzheimer's disease with aging.A review of β-amyloid neuroimaging in Alzheimer's disease.Multivariate statistical mapping of spectroscopic imaging data Comparison of New Tau PET-Tracer Candidates With [18F]T808 and [18F]T807 Dipeptidyl peptidase 10 (DPP10(789)): a voltage gated potassium channel associated protein is abnormally expressed in Alzheimer's and other neurodegenerative diseases.cis-Glyco-fused benzopyran compounds as new amyloid-β peptide ligands.Quantitative changes in the mitochondrial proteome from subjects with mild cognitive impairment, early stage, and late stage Alzheimer's disease.A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study.Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?Increased brain iron coincides with early plaque formation in a mouse model of Alzheimer's disease.Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.Interleukin17A Promotes Postoperative Cognitive Dysfunction by Triggering β-Amyloid Accumulation via the Transforming Growth Factor-β (TGFβ)/Smad Signaling Pathway In Vivo Differences between Two Optical Isomers of Radioiodinated o-iodo-trans-decalinvesamicol for Use as a Radioligand for the Vesicular Acetylcholine Transporter.Amelioration of cognitive impairments in APPswe/PS1dE9 mice is associated with metabolites alteration induced by total salvianolic acid.Constructing longitudinal disease progression curves using sparse, short-term individual data with an application to Alzheimer's disease.SPION-enhanced magnetic resonance imaging of Alzheimer's disease plaques in AβPP/PS-1 transgenic mouse brain.Enviromimetics: exploring gene environment interactions to identify therapeutic targets for brain disorders.Present and prospective clinical therapeutic regimens for Alzheimer's disease.Amyloid-β Peptides and Tau Protein as Biomarkers in Cerebrospinal and Interstitial Fluid Following Traumatic Brain Injury: A Review of Experimental and Clinical Studies.Alzheimer's disease: the lipid connection.Folic Acid Supplementation Mitigates Alzheimer's Disease by Reducing Inflammation: A Randomized Controlled Trial.Hippocampal Amyloid Burden with Downstream Fusiform Gyrus Atrophy Correlate with Face Matching Task Scores in Early Stage Alzheimer's Disease.Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease.Aβ monomers transiently sample oligomer and fibril-like configurations: ensemble characterization using a combined MD/NMR approach Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease Amyloid plaques in PSAPP mice bind less metal than plaques in human Alzheimer's disease.Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies.Copper complexes of bis(thiosemicarbazones): from chemotherapeutics to diagnostic and therapeutic radiopharmaceuticals.Amyloid imaging.Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes.Metal complexes designed to bind to amyloid-β for the diagnosis and treatment of Alzheimer's disease.In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease.Cerebrospinal Fluid Amyloid-β 42, Total Tau, and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimer's Disease.Brain phylogeny, ontogeny and dysfunction: integrating evolutionary, developmental and clinical perspectives in cognitive neuroscience.New Tacrine Hybrids with Natural-Based Cysteine Derivatives as Multitargeted Drugs for Potential Treatment of Alzheimer's Disease.Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer's disease.

P2860

Q22252572-8414C89C-F5EA-4F5D-B20C-74DC144CD5E0 Q24654919-55EA1A77-1924-4C55-A958-85A52150C40D Q26749755-2CDB4C72-EC8A-48C8-93DE-E3E73C60465E Q30576714-F6B0F908-10CF-4B55-A687-B22E16F5CBD6 Q30587668-7C6B5D42-F336-483E-80DC-F7A1FAE1047B Q30870063-6AE1FFE6-520C-4089-8AC7-8BAA948A07FA Q33517037-27A170B6-B719-457C-9EA3-26172D2023D2 Q33795224-AB129D4C-91CA-4D09-B6D8-BFAA892A5F30 Q33855018-319AB87E-3676-4374-84F2-74F8DBBF510E Q34000176-50515558-2A16-42F9-BFAE-0CB928A0A696 Q34002680-B8D8D50F-DA01-4952-A5E9-DE50763715CA Q34341870-F8CA5CA3-2863-4240-B024-1AB88486CC4C Q34419108-2FCC0D2D-8AA9-425D-B82C-3741D2D31BF4 Q34543407-5D3CB2EA-178C-488B-9E6A-B3CD1D99B904 Q34606557-E583F73E-8B3D-49AD-A204-AA26C3BE811C Q35824163-71CCC2AE-7EF1-4C29-AE7E-EAF4089680AE Q35890404-A251868C-E0F7-4DF3-A536-216378A61E8D Q36328483-51E47BB9-9500-4CC6-81EC-C02D9D92782F Q36356412-C7593AB6-8978-424A-A575-296C68A3DE43 Q36710294-0D399C59-9D08-449E-AD34-846C411E903A Q36871981-913B9D56-9DF4-4281-9D17-9BEEF0244623 Q36876447-02237A29-17AE-4093-A8F0-B1FFAF8248C0 Q36955963-F060277F-EC99-4351-A27C-28664E5AB069 Q36994590-4DAAE614-008A-49DD-BFE7-F9E3568DB902 Q37009939-606E1267-7BC0-4263-BB2F-87A273C000AD Q37014423-56F70C83-9ED3-4993-B152-15F2C0726992 Q37184248-76D717A1-574B-48E4-9DD9-5C4376175F47 Q37191689-9E47C6D1-78F1-401C-AE6A-98F400AA8FA7 Q37215837-2201A83F-2296-4E04-AFEB-3740262FC8AD Q37353039-B2FF6ABF-D10D-4C37-9D3C-B5F1F4A1601A Q37691087-84EBF2EA-BDBE-418F-8B28-23AFF2A353BC Q37853427-5B1EFB9C-1E0A-4722-BD6E-F3249F6EF6A8 Q37897691-1CCD67BC-58B0-4DC7-B613-997621C7FDD7 Q38125769-1F29EB5D-FE62-4BE1-8B6C-F8C94C068987 Q38199617-CE1885DA-BB60-4C2D-9F19-2D669945B4CE Q38436447-1ADDB1B5-4E00-4748-8868-6B1BCF620E38 Q38616051-F1093857-CA1B-4C1E-967E-3363E3455067 Q38764880-B981E9F5-5CFF-4297-941E-3CE520F46616 Q38845131-D8F35B3A-E600-4FDD-AB01-65BA39868152 Q38864839-0FC8B9AD-0437-4925-AB44-85BAA07B7D6E

P2860

Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics.

http://www.wikidata.org/entity/Q31047131

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Molecular mechanisms for Alzhe ...... neuroimaging and therapeutics.

@ast

Molecular mechanisms for Alzhe ...... neuroimaging and therapeutics.

@en

type

label

Molecular mechanisms for Alzhe ...... neuroimaging and therapeutics.

@ast

Molecular mechanisms for Alzhe ...... neuroimaging and therapeutics.

@en

prefLabel

Molecular mechanisms for Alzhe ...... neuroimaging and therapeutics.

@ast

Molecular mechanisms for Alzhe ...... neuroimaging and therapeutics.

@en

P1433

Q31047131-E6C461A5-F986-4DA8-8019-24794B6F5BA9

P1476

Q31047131-3972D954-9A2C-41DF-A748-4D4F0779305B

P2093

Q31047131-8B250A2D-9314-4D7F-9188-549A2F5707DE

Q31047131-B40CB688-C74E-41C8-BF10-A7A99EF4317C

Q31047131-E0A93E0A-74BB-49E0-A41C-9D2B58BDA276

P2860

Q31047131-0020C283-E000-4539-907C-B2E3C61467C7

Q31047131-018932A8-97C5-475F-8EB5-5DE57F211C75

Q31047131-02B29652-8095-4BF3-B342-FBB548A60222

Q31047131-02D2D364-F95B-44D1-B399-97A977A5FF3B

Q31047131-0463447C-DC92-418B-882B-FEE020BC5F59

Q31047131-077DAAC5-71BE-4ECA-A036-0074DEF6FDDC

Q31047131-08035A73-F63A-4F90-BC61-46E8B7ECC398

Q31047131-081DA087-00F6-4EEF-ADB3-6467D269BDDC

Q31047131-0835FABB-45D3-4445-8C0E-1D7FE040F33D

Q31047131-08A93D8E-68DC-46F7-A88E-71A1E6F1687D

P304

Q31047131-C117ADF3-DDAF-4024-ACA1-338172CC8EF3

P31

Q31047131-1CFF61CD-C89B-41BF-B4EC-7F5EDDBABAA0

P356

Q31047131-0167D385-D4EE-4A3A-A52B-753BE86EA0D0

P407

Q31047131-0F682C90-B5BF-4180-B42A-E871DDAFEE09

P433

Q31047131-483673F8-E3E8-4936-87CA-8ECB92C778A9

P478

Q31047131-AA3434F8-F55F-45A9-B6F6-6C95C644B8D8

P50

Q31047131-378FFE7A-1E62-4C39-8E42-45C39628A3F4

P577

Q31047131-7D1B1580-DB86-4360-A7B4-5C16348A0E09

P5875

Q31047131-6F744C7E-BE58-4FC5-9D87-A49A3864BFD6

P698

Q31047131-CEE84FEC-9697-4C92-9849-5CFEA19DD912

P921

Q31047131-1FA5EC37-38B3-4720-B0BC-9FE1EEC5D48B

Q31047131-FD868F16-9753-4FE4-A667-34735C9047CA

P356

J.1471-4159.2006.03989.X

P1433

Journal of Neurochemistry

P1476

Molecular mechanisms for Alzhe ...... neuroimaging and therapeutics.

@en

P2093

Kevin J Barnham

http://www.w3.org/2001/XMLSchema#string

Roberto Cappai

http://www.w3.org/2001/XMLSchema#string

Victor L Villemagne

http://www.w3.org/2001/XMLSchema#string

P2860

Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein.

Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice

Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease

Amyloid plaque core protein in Alzheimer disease and Down syndrome

P304

1700-1725

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1471-4159.2006.03989.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P50

Colin L. Masters

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6978467

http://www.w3.org/2001/XMLSchema#string

P698

16805778

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease